Regeneron Pharmaceuticals, Inc is a biotechnology business with stocks listed in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$557.46 – an increase of 0.4% over the previous week.
How to buy shares in Regeneron Pharmaceuticals
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Regeneron Pharmaceuticals. Find the share by name or ticker symbol: REGN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Regeneron Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$557.46, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Regeneron Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Regeneron Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Regeneron Pharmaceuticals key stats
- Compare share trading platforms
- Is Regeneron Pharmaceuticals stock a buy or sell?
- Regeneron Pharmaceuticals performance over time
- Can I short Regeneron Pharmaceuticals shares?
- Is Regeneron Pharmaceuticals suitable for ethical investing?
- Are Regeneron Pharmaceuticals shares over-valued?
- Regeneron Pharmaceuticals's financials
- How volatile are Regeneron Pharmaceuticals shares?
- Does Regeneron Pharmaceuticals pay a dividend?
- Other common questions
How has coronavirus impacted Regeneron Pharmaceuticals's share price?
Since the stock market crash in March caused by coronavirus, Regeneron Pharmaceuticals's share price has had significant positive movement.
Its last market close was US$557.46, which is 27.68% up on its pre-crash value of US$403.15 and 64.25% up on the lowest point reached during the March crash when the shares fell as low as US$339.39.
If you had bought US$1,000 worth of Regeneron Pharmaceuticals shares at the start of February 2020, those shares would have been worth US$1,335.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$1,633.36.
Regeneron Pharmaceuticals share priceUse our graph to track the performance of REGN stocks over time.
Regeneron Pharmaceuticals shares at a glance
|Latest market close||USD$557.46|
|52-week range||USD$271.37 - USD$660|
|50-day moving average||USD$599.1335|
|200-day moving average||USD$570.9896|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$25.827|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Regeneron Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Regeneron Pharmaceuticals price performance over time
|1 week (2020-09-14)||-1.19%|
|1 month (2020-08-25)||-8.69%|
|3 months (2020-06-21)||N/A|
|6 months (2020-03-23)||22.35%|
|1 year (2019-09-21)||N/A|
|2 years (2018-09-21)||42.84%|
|3 years (2017-09-21)||28.61%|
|5 years (2015-09-21)||5.30%|
Is Regeneron Pharmaceuticals under- or over-valued?
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's P/E ratio
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Regeneron Pharmaceuticals shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's PEG ratio
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3335. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3 billion (£2.4 billion).
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Regeneron Pharmaceuticals financials
|Revenue TTM||US$8.7 billion|
|Operating margin TTM||32.28%|
|Gross profit TTM||US$4 billion|
|Return on assets TTM||12.71%|
|Return on equity TTM||31.72%|
|Market capitalisation||US$59.1 billion|
TTM: trailing 12 months
Shorting Regeneron Pharmaceuticals shares
There are currently 2.1 million Regeneron Pharmaceuticals shares held short by investors – that's known as Regeneron Pharmaceuticals's "short interest". This figure is 14.1% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting Regeneron Pharmaceuticals shares can be evaluated.
Regeneron Pharmaceuticals's "short interest ratio" (SIR)
Regeneron Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Regeneron Pharmaceuticals shares currently shorted divided by the average quantity of Regeneron Pharmaceuticals shares traded daily (recently around 829119.140625). Regeneron Pharmaceuticals's SIR currently stands at 2.56. In other words for every 100,000 Regeneron Pharmaceuticals shares traded daily on the market, roughly 2560 shares are currently held short.
However Regeneron Pharmaceuticals's short interest can also be evaluated against the total number of Regeneron Pharmaceuticals shares, or, against the total number of tradable Regeneron Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regeneron Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Regeneron Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0207% of the tradable shares (for every 100,000 tradable Regeneron Pharmaceuticals shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regeneron Pharmaceuticals.
Find out more about how you can short Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Regeneron Pharmaceuticals's total ESG risk score
Total ESG risk: 23.31
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 23.31 (as at 07/31/2020) is pretty good – landing it in it in the 28th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Regeneron Pharmaceuticals's environmental score
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's social score
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Regeneron Pharmaceuticals's governance score
Governance score: 7.35/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||23.31|
|Total ESG percentile||28.12|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
Regeneron Pharmaceuticals share dividends
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Regeneron Pharmaceuticals share price volatility
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as US$271.37 up to US$660. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.4933. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Frequently asked questions
Ask an Expert